

HUMAN INTERLEUKIN-7 ELISA

Product Data Sheet

Cat. No.: RGP014R

For Research Use Only

Page 1 of 16 ENG.002.A

CONTENTS

1.	INTENDED USE	3
2.	PRINCIPLE OF THE METHOD	3
3.	REAGENTS PROVIDED AND RECONSTITUTION	4
4.	MATERIAL REQUIRED BUT NOT PROVIDED	4
5.	STORAGE INSTRUCTIONS	5
6.	SPECIMEN COLLECTION, PROCESSING & STORAGE	5
7.	SAFETY & PRECAUTIONS FOR USE	6
8.	ASSAY PREPARATION	7
9.	METHOD	10
10.	DATA ANALYSIS	11
11.	ASSAY LIMITATIONS	12
12.	PERFORMANCE CHARACTERISTICS	13
13.	REFERENCES	13
14.	ASSAY SUMMARY	14

- This kit is manufactured by:
 BioVendor Laboratorní medicína a.s.
- Use only the current version of Product Data Sheet enclosed with the kit!

Page 2 of 16 ENG.002.A

1. INTENDED USE

The Human Interleukin-7 ELISA is to be used for the in-vitro quantitative determination of interleukin 7 (IL-7) in human serum, plasma, buffered solutions or cell culture medium. The assay will recognize both natural and recombinant human IL-7.

This kit has been configured for research use only.

2. PRINCIPLE OF THE METHOD

The IL-7 Kit is a solid phase sandwich Enzyme Linked-Immuno- Sorbent Assay (ELISA).

A monoclonal antibody specific for IL-7 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known IL-7 concentrations, control specimens and unknowns are pipetted into these wells.

During the first incubation, the IL-7 antigen and a biotinylated monoclonal antibody specific for IL-7 are simultaneously incubated.

After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove all the unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of IL-7 present in the samples.

Page 3 of 16 ENG.002.A

3. REAGENTS PROVIDED AND RECONSTITUTION

REAGENTS (Store at 2-8°C)	Quantity	State
96 well microtiter strip plate	96 wells	Ready to use (Pre-coated)
Plastic plate covers	2	n/a
Standard: 200 pg/ml	2 vials	Reconstitute as directed in Quality Control Sheet (see reagent preparation)
Standard Diluent (Buffer)	1 vial (25 ml)	10x Concentrate, dilute in distilled water (see reagent preparation)
Standard Diluent (Human serum)	1 (7ml)	Ready to use
Control	2 vials	Reconstitute as directed in Quality Control Sheet (see reagent preparation)
Biotinylated anti-IL-7	1 vial (0.4 ml)	Dilute in Biotinylated antibody diluent (see reagent preparation)
Biotinylated Antibody diluent	1 vial (7 ml)	Ready to use
Streptavidin-HRP	2 vials (5μl)	Add 0.5ml of HRP diluent prior to use (see reagent preparation)
HRP Diluent	1 vial (23 ml)	Ready to use
Wash Buffer	1 vial (10 ml)	200x Concentrate dilute in distilled water (see reagent preparation)
TMB Substrate:	1 vial (11 ml)	Ready to use
H ₂ SO ₄ : Stop Reagent	1 vial (11 ml)	Ready to use

4. MATERIAL REQUIRED BUT NOT PROVIDED

- Microtitre plate reader fitted with appropriate filters (450 nm required with optional 630 nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000 µl adjustable single channel micropipettes with disposable tips
- 50-300 μl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

Page 4 of 16 ENG.002.A

5. STORAGE INSTRUCTIONS

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

Wash Buffer: Once prepared store at 2-8°C for up to 1 week

Standard Diluent Buffer: Once prepared store at 2-8°C for up to 1 week **Standards / Controls**: Once prepared use immediately and do not store

Biotinylated Secondary Antibody: Once prepared use immediately and do not store

Streptavidin-HRP: Once prepared use immediately and do not store

6. SPECIMEN COLLECTION, PROCESSING & STORAGE

Cell culture supernatants, serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Avoid any inintentional stimulation of the cells by the procedure. Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. For that, after clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA,citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

Page 5 of 16 ENG.002.A

7. SAFETY & PRECAUTIONS FOR USE

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g.CDC/NIH Health manual: "Biosafety in Microbiological and Biomedical Laboratories" 1984
- The human serum included in this kit have been tested and found non reactive for HbsAg, anti HIV1 & 2 and anti VHC. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore handling of reagents, serum or plasma specimens should be in accordance with local safety procedures
- Laboratory gloves should be worn at all times
- Avoid any skin contact with H₂SO₄ and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H₂SO₄ and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact
 of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid
 direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate


Page 6 of 16 ENG.002.A

Bring all reagents to room temperature before use

8.1 Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**. Remove sufficient Microwell Strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

Example plate layout (example shown for a 6 point standard curve)



All remaining empty wells can be used to test samples in duplicate

Page 7 of 16 ENG.002.A

8.2. Preparation of Wash Buffer

Dilute the (200x) wash buffer concentrate 200 fold with distilled water to give a 1x working solution. Pour entire contents (10 ml) of the Washing Buffer Concentrate into a clean 2,000 ml graduated cylinder. Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2°-8°C for up to 1 week.

8.3. Preparation of Standard Diluent Buffer

Add the contents of the vial (10x concentrate) to 225ml of distilled water before use. This solution can be stored at 2-8°C for up to 1 week.

8.4. Preparation of Standard

Depending on the type of samples you are assaying, the kit includes two standard diluents. Because biologicals fluids might contain proteases or cytokine-binding proteins that could modify the recognition of the cytokine you want to measure. You should reconstitute standard vials with the most appropriate standard diluent.

For serum and plasma samples use standard diluent human serum and for cells culture supernatants use Standard diluent buffer.

Standard vials must be reconstituted with the volume of standard diluent shown on the vial immediately prior to use. This reconstitution gives a stock solution of 200 pg/ml of IL-7. **Mix the reconstituted standard gently by inversion only**. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 200 to 6.25 pg/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200 of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 200 pg/ml
- Add 100 μl of appropriate standard diluent to the remaining standard wells B1 and B2 to F1 and F2
- Transfer 100 μl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100 μl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 200 pg/ml to 6.25 pg/ml
- Discard 100 μl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred directly into the relevant wells.

Page 8 of 16 ENG.002.A

8.5. Preparation of Controls

Freeze-dried control vials should also be reconstituted with the most appropriate standard diluent to your samples. For serum and plasma samples use standard diluent: human serum and for cells culture supernatants use Standard diluent buffer. Control have to be reconstituted with the volume of standard buffer diluent indicated on the vial. Reconstitution of the freeze-dried material with the indicated volume, will give a solution for which the IL-7 concentration is stated on the vial.

Do not store after use.

8.6. Preparation of Biotinylated anti-IL-7

It is recommended this reagent is prepared immediately before use. Dilute the biotinylated anti-IL-7 with the biotinylated antibody diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number	of	wells	Biotinylated	Biotinylated Antibody
required			Antibody (μl)	Diluent (μl)
16			40	1060
24			60	1590
32			80	2120
48			120	3180
96			240	6360

8.7. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute the 5μ l vial with 0.5ml of HRP diluent **immediately before use.** Do-not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of Wells	Streptavidin-HRP(µI)	Strep-HRP Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

Page 9 of 16 ENG.002.A

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vial which must be mixed gently by inversion only.

Prepare all reagents as shown in section 8.

Note: Final preparation of Biotinylated anti-IL-7 (section 8.6) and Streptavidin-HRP (section 8.7) should occur immediately before use.

Assay Step		Details					
1.	Addition	Add 100ll of each standard , sample , control and zero (standard diluent) in duplicate to appropriate number of wells					
2.	Addition	Add 501 of diluted biotinylated anti-IL-7 to all wells					
3.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 2 hours					
4.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times					
5.	Addition	Add 100µl of Streptavidin-HRP solution into all wells					
6.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 30 min					
7.	Wash	Repeat wash step 4.					
8.	Addition	Add 100µl of ready-to-use TMB Substrate Solution into all wells					
9.	Incubation	Incubate in the dark for 10-20 minutes * at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil					
10.	Addition	Add 100µl of H₂SO₄:Stop Reagent into all wells					
Read the absorbance value of each well (immediately after step 10.) on a							

Read the absorbance value of each well (immediately after step 10.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).

Page 10 of 16 ENG.002.A

^{*}Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range

10. DATA ANALYSIS


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding Human IL-7 standard concentration on the horizontal axis.

The amount of IL-7 in each sample is determined by extrapolating OD values against IL-7 standard concentrations using the standard curve.

Example IL-7 Standard curve

Standard	IL-7 (pg/ml)	OD (450nm) Mean	CV (%)
1	200	2.311	4.0
2	100	1.496	2.1
3	50	0.929	0.9
4	25	0.545	3.1
5	12.5	0.362	3.9
6	6.25	0.282	1.0
Zero	0	0.136	-



Note: curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

Page 11 of 16 ENG.002.A

11. ASSAY LIMITATIONS

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore a fresh standard curve must be prepared and run for every assay.

Page 12 of 16 ENG.002.A

12. PERFORMANCE CHARACTERISTICS

12.1 Sensitivity

The minimum detectable dose of IL-7 is less than 3 pg/ml.

This has been determined by adding 3 standard deviations to the mean optical density obtained when the zero standard was assayed 36 times.

12.2 Precision

Sample	n	Mean (pg/mL)	SD	CV%	Sample	n	Mean (pg/mL)	SD	CV%
Α	8	198.7	1.667	0.83	Α	29	198.9	3.772	1.89
В	8	28.69	1.118	3.86	В	29	25.68	1.505	5.84

12.4 Dilution Linearity

A human serum pool containing 200 pg/ml of IL-7 was serially diluted in standard buffer diluent over the range of the assay. Linear regression of samples versus the expected concentration vielded a correlation coefficient of 0.99.

12.5 Spiking Recovery

Recovery of IL-7 added to pooled normal serum was 97.6% (88.3% to 110.2 %) for IL-7 concentration ranging from 200 to 6 pg/ml.

13. REFERENCES

- 1. Churchman, S. M. and F. Ponchel, Rheumatology, 2008;47: 753-759 Interleukin-7 in rheumatoid arthritis
- 2. Kang I. et al., J. Imunol., 2004; 173(1): 673 681
 Age-Associated Change in the Frequency of Memory CD4 + T Cells. Impairs Long Term CD4+T Cell Responses to Influenza Vaccine
- 3. Sereti, I. et al., Blood,2009;113(25): 6304-6314. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
- 4. Sportes, C.et al., Clin. Cancer Res., 2010;16(2): 727-735

 Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy
- 5. van Roon, J. A. et al., Ann Rheum Dis.,2007; 66(5): 664-9. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis
- 6. van Roon, J. A. et al., Ann Rheum Dis.,2003; 62(2): 113-9. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis

Page 13 of 16 ENG.002.A

Total procedure length 2 h 45 mn

Add 100µl of sample or diluted standard or control

₩

Add 50µl of diluted biotinylated Detection antibody to all wells

11

Incubate 2 hours at room temperature

 $\downarrow \downarrow$

Wash three times

 \Downarrow


Add $100\mu I$ of streptavidin-HRP to all wells

 $\downarrow \downarrow$

Incubate 30min at room temperature

Page 14 of 16 ENG.002.A

Page 15 of 16 ENG.002.A



BioVendor - Laboratorní medicína, a.s.

Karasek 1767/1, 621 00 Brno, Czech Republic Phone: +420-549-124-185, Fax: +420-549-211-460 E-mail: info@biovendor.com, sales@biovendor.com

Web: www.biovendor.com

There are BioVendor branches and distributors near you.

To find the office closest to you, visit www.biovendor.com/contact



Page 16 of 16 ENG.002.A